Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1997027885) PREPARATION OF BIOLOGICAL MATERIAL FOR IMPLANTS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1997/027885 International Application No.: PCT/CA1997/000056
Publication Date: 07.08.1997 International Filing Date: 28.01.1997
IPC:
A61L 27/36 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
L
METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
27
Materials for prostheses or for coating prostheses
36
containing ingredients of undetermined constitution or reaction products thereof
Applicants:
LEE, John, Michael [CA/CA]; CA
Inventors:
LEE, John, Michael; CA
Agent:
GALLOWAY, Warren, John; Sim & McBurney 6th floor 330 University Avenue Toronto, Ontario M5G 1R7, CA
Priority Data:
2,168,28329.01.1996CA
Title (EN) PREPARATION OF BIOLOGICAL MATERIAL FOR IMPLANTS
(FR) PREPARATION DE MATIERE BIOLOGIQUE POUR IMPLANTS
Abstract:
(EN) A method for preparation of biological material for a medical device. Samples of intact or acellular tissue of biological material are treated in vitro with (i) a water-soluble carbodiimide of the formula R1-N=C=N-R2, wherein R1 and R2 are independently selected from alkyl and alkylamino groups, in combination with (ii) an agent that forms a stable activated ester with said carbodiimide. The agent to stabilize the activated esters is preferably N-hydroxysuccinimide or N-hydroxysulfosuccinimide. The preferred carbodiimide is 1-ethyl-3-(dimethylaminopropyl)-carbodiimide. The method reduces inflammatory reactions of xenografts.
(FR) La présente invention concerne un procédé de préparation de matière biologique pour un appareil médical. Des échantillons de tissu intact ou acellulaire de matière biologique sont traités in vitro avec (a) une cyanamide soluble dans l'eau, de formule R1-N=C=N-R2, dans laquelle R1 et R2 sont choisis de manière indépendante parmi des groupes alkyle et alkylamino, en combinaison avec (b) un agent qui forme, avec cette cyanamide, un ester activé stable. L'agent de stabilisation des esters activés est de préférence de la N-hydroxy-succinimide ou de la N-hydroxysulfosuccinimide. La cyanamide préférée est la 1-éthyl-3-(diméthylaminopropyl)-cyanamide. Le procédé selon l'invention réduit les réactions inflammatoires des hétérogreffes.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN
African Regional Intellectual Property Organization (ARIPO) (KE, LS, MW, SD, SZ, UG)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
AU1997014340